All In Biotech

Drug Trial Radar · NCT07304518

Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase II Trial of PRT-064040 Nasal Spray for the Acute Treatment of Migraine

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 456 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

456

Planned (sponsor's estimate)

Start

Jan 26, 2026

Primary completion

Sep 2026

Study completion Oct 2026

Sponsor

Sponsor type
Industry
First posted
Dec 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.

Conditions

  • Migraine

Interventions

  • PRT-064040 nasal sprayDrug

    A single dose of PRT-064040 nasal spray

  • PlaceboDrug

    A single dose of placebo matched to PRT-064040 nasal spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Freedom From Pain at 2 Hours Post-doseTime frame: 2 hours post-dose
  2. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-doseTime frame: 2 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Medical Center of PLA General Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.